JIANGSU HENGRUI MEDICINE CO., LTD.

No.7, Kunlunshan Road, Economic & Technological Development Zone, Lianyungang, Jiangsu, China

Tel

0086-518-85473511 / 85475919

0086-518-85465746










HENGRUI MEDICINE





Speech by the Chairman of the Board

As an innovative pharmaceutical enterprise, we have always put the health demand of people in China and even the whole world in the first place, and have been devoted to improving the medical treatment and health conditions. We are dedicated to creating a healthy life for all humanity, and conveying the power of love and hope for human beings.

How should we help patients relieve the pain of diseases? Is there any kind of medicine that can successfully meet the need of unsolved clinical problems? How can we solve the problem of accessibility and sustainability of new medicines by means of speeding up innovation? We remind ourselves of these questions every day and we are committed to answering them.

So far, we have made great progress in areas such as antineoplastic, diabetes, cardiovascular, bio-pharmaceutical, and the immune system, with one or two new medicines coming up each year, which benefits our patients greatly. In the meanwhile, we have enhanced our cooperation with foreign business partners and taken efforts to promote China-made medicines to the world to live up to our aims.

In the future, I believe Hengrui Medicine will continually stand by the concept of "Science & Technology for a Better Life". It will sail afar with a strong sense of love and responsibility!

"We have enhanced our cooperation with foreign business partners and taken efforts to promote China-made medicines to the world to live up to our aims." Piaoyang Sun Chairman of the Board



HENGRUI (USA) LTD.

Hengrui Medical Japan Corp.

Cadiasun Pharman GmbH

Jiangsu Hengrui Medicine Sales

HENGRUIMedicine

Jiangsu Singch Pharmaceutical Co., Ltd.

Chengdu Suncadia Pharmaceuticals Co., Ltd.

Chengdu Xinyue Medicine Co., Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceutical Co., Ltd.

Callisyn BioMedical-Suzhou

Company Profile

Jiangsu Hengrui Medicine Co., Ltd., established in 1970 and headquartered in Lianyungang, Jiangsu Province, is not only the front-runner in China's innovative medicine, but also a well-known R&D center of antineoplastics and surgical medicine in China. Taking the slogan that "Science & Technology for a Better Life", Hengrui Medicine is dedicated to researching, developing, and promoting innovative medicine with high quality. We aim to help doctors solve clinical problems, help patients be cured, and help improve the standard of health for all humanity.

Hengrui Medicine focuses on fulfilling the unmet clinical demands, promoting innovation in technology, and serving the health of humanity. Hengrui Medicine invests 10% of its annual turnovers in research and development, and has constituted a thorough innovation system with R&D centers and clinical division in New Jersey, Shanghai, Chengdu, and Lianyungang. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. In 2014, Hengrui Medicine independently developed a 1.1 Class innovative medicine named Apatinib, the world's first small molecule anti-angiogenesis targeting agent to treat late gastric cancer, bringing hope for patients suffering from late stage gastric cancer. Hengrui Medicine welcomes all kinds of high-level talents and professionals from home and abroad and now is equipped with a R&D team of more than 1,300. The diversification of products, comprehensive product lines, and the pursuit of innovation endow us with great competitive advantage.

Hengrui Medicine is committed to producing high quality medicines to help more patients have access to better and affordable medical resources more timely. Adhering to the highest level of the US FDA management standards to manage the production, Hengrui Medicine is the first pharmaceutical enterprise that sells domestic injectable products overseas to Europe, US, and Japan. By taking global coordination, we have been creating more value for our patients and stake holders, and curbed the rapid increase of global health care cost. Hengrui Medicine now produces and sells injectable products, oral dosages, and many other types of medicine in the European and US markets. No matter it is in cities or rural areas, we are more accessible to patients, clinicians, and business partners. Hengrui Medicine has won great reputation and respect by providing high quality and reliable products.

The future depends on the health of people, and it is innovation that establishes a good brand. Hengrui Medicine will take continuous efforts to serve the great cause of human health with more and more new and high quality medicines.

Growing Course

• 1970

Hengrui Medicine's predecessor
—Lianyungang Pharmaceutical
Factory was established

1984

Hengrui Medicine's first anticancer drug
—Etoposide API and drug product
were put into production

1995

APIs of Etoposide and Ifosfamide passed US FDA inspection

1997

Jiangsu Hengrui Medicine Co., Ltd. was incorporated

• 2011

Chengdu Suncadia Pharmaceuticals Co., Ltd. was established

No.1 Finished Product Plant was put into use in Lianyungang

• 1999

2000

Shanghai Hengrui Pharmaceutical Co., Ltd. was established

• 2012

First injectable product Irinotecan Hydrochloride Injection was launched in US market

2005

USA branch HENGRUI (USA) Ltd. was established

2006

Oxaliplatin API got CEP certificate Callisyn Biomedical-Suzhou was established • 2014

Japanese branch Hengrui Medical Japan Corp. was established

Finished product Cyclophosphamide for Injection was launched in US and EU market, and Oxaliplatin Injection was launched in US market

Subsidiary company Cadiasun Pharman GmbH was formally established in Germany

Hengrui's innovative drug "Methanesulfonic Acid Apatinib Tablet' was approved by CFDA of China

2008

New API manufacturing plant in Lianyungang was put into production

• 2015

Suzhou Suncadia Biopharmaceutical Co., Ltd. was established

2010

Irinotecan HCl API passed Japanese PMDA inspection

2016

Sevoflurane Inhalation Anaesthetic was launched in EU and US Desflurane Inhalation and Caspofungin Acetate for Injection received Netherlands GMP certificate

Global Presence

Germany

Chengdu

Suzhou

USA Japan Shanghai • • • • • • • • • • • •



Lianyungang

Subsidiary Company

HENGRUI (USA) LTD.

Hengrui Medical Japan Corp.

Cadisun Pharman GmbH

Jiangsu Hengrui Medicine Sales

Jiangsu Singch Pharmaceutical Co., Ltd.

Chengdu Suncadia Pharmaceuticals Co., Ltd.

Chengdu Xinyue Medicine Co., Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceutical Co., Ltd.

Callisyn BioMedical-Suzhou

R&D center





Shanghai



Chengdu



Lianyungang



Clinical Division

Manufacturing Site



API Branch (Lianyungang)





Lianyungang

No.1 Finished Product Plant (Lianyungang) No.2 Finished Product Plant (Lianyungang)



Shanghai / FDF



Chengdu / FDF



Chengdu/API



Suzhou/FDF



Suzhou/ Medical Device

Quality Management System




Product quality is the foundation for enterprise survival and development. Hengrui has always been depending on the quality as life and focused on exerting talents, equipment and other advantages. Annually Hengrui invests tens of millions to upgrade the technology and has established a sound quality control system. Most products' quality has reached USP and EP standards. In 2010 US FDA conducted PAI inspection to one of Hengrui's sterile injection, it was the first FDA's inspection to Chinese sterile injection. In development, Hengrui Medicine maintains a quality superior to its peers, and strives to make the company the leader domestically and competitor internationally in new drug quality standards.

Quality Authentication







Based on strong development capabilities and sound quality management system, many of Hengrui's API have been approved by US FDA, Australia TGA, PMDA and EDQM, since 2008, Hengrui began to submit ANDAs and FDF dossiers to US FDA and EU countries every year, and since 2012, Hengrui's drug products were formally launched in US and EU market.





GMP AUDUT ON API SITE











INJECTION







CYCLOPHO-**SPHAMIDE** FOR INJ.









OXALIPLATIN LETROZOLE FOR INJ.



OXALIPLATIN FOR INJ.

GMP AUDIT ON FDF SITE



Finished Dosage Form List

Innovative medicines




Generics Medicines

Antineoplastic












Enalapriline Maleate Tablets

10mg


Clarithromycin Tablets

50mg; 0.125g; 0.25g

Anaesthetic



Others -



Clarithromycin Sustained Release Tablets

0.5g

Sustained Release Capsules Cetirizine:5mg;

Pseudoephedrine HCl:120mg



